Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884407 | 0.94 | CHRNA7 (0.72) | CHRNA7TSHRPTGS2SMN1; SMN2MAPT | |
| SCHEMBL2886487 | 0.93 | CHRNA7 (0.74) | CHRNA7TSHRPTGS2SMN1; SMN2MAPT | |
| SCHEMBL16403251 | 0.87 | CHRNA7 (0.81) | CHRNA7MAPK1MAPTLMNA | |
| SCHEMBL5922348 | 0.84 | LMNA (0.69) | CHRNA7TSHRSMN1; SMN2MAPTLMNA | |
| SCHEMBL3015089 | 0.83 | CHRNA7 (0.86) | CHRNA7PTGS2 | |
| SCHEMBL4638659 | 0.82 | NOTUM (0.70) | CHRNA7PTGS2 | |
| SCHEMBL3027578 | 0.82 | CHRNA7 (0.77) | CHRNA7MAPK1LMNA | |
| SCHEMBL7167950 | 0.82 | MAPT (0.75) | CHRNA7TSHRPTGS2SMN1; SMN2MAPT | |
| SCHEMBL2888752 | 0.81 | CHRNA7 (0.72) | CHRNA7TSHRSMN1; SMN2MAPK1MAPT | |
| SCHEMBL7168904 | 0.81 | CHRNA7 (0.60) | CHRNA7TSHRSMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124489-B1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3124489-A1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | Fibrogen, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2016078-B1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2016-06-15 | — | — | EP | disclosed |
| US-7696223-B2 | [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) | FIBROGEN, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2016078-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007115315-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | CHRNA7 4787/4885TSHR 1319/4885PTGS2 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.